| Filed On | Filing |
|---|---|
| 01 Oct 2026 |
8-K: Entry into a Material Definitive Agreement; Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement
As previously disclosed by TransCode Therapeutics, Inc. (the “Company”) in a Current Report on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on April 7, 2026, the Company entered into a Standby Equity Purchase Ag... |
| 28 Sep 2026 |
8-K: Other Events
TransCode Reports Continued Disease Stabilization and Extended Treatment Duration with TTX-MC138 in Ongoing Phase 1a Clinical Trial Follow-Up |
| 21 Sep 2026 |
Form 3: Tattory John A, Interim CFO
No securities owned |
| 11 Sep 2026 |
Form 4: Fitzgerald Thomas A, Director
Granted 185,000 Stock Option (right to buy) |
| 11 Sep 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
This letter agreement follows our conversation of August 19, 2026, regarding your employment with TransCode Therapeutics, Inc. (the “Company”) and confirms the termination of your employment with the Company effective September 9, 2026 (... |
| 14 Aug 2026 | 10-Q |
| 05 Aug 2026 |
Form 4: DEFJ, Llc, 10% owner and 1 other
Received 13,834,441 shares by conversion |
| 05 Aug 2026 |
Form 3: DEFJ, Llc, 10% owner and 1 other
Holds 300,040 shares of Common Stock |
| 03 Aug 2026 | SCHEDULE 13D/A |
| 03 Aug 2026 | 8-K: Material Modification to Rights of Security Holders; Amendments to Articles/Bylaws; Change in Fiscal Year |
| 28 Jul 2026 | SCHEDULE 13G |
| 28 Jul 2026 | SCHEDULE 13G |
| 28 Jul 2026 | SCHEDULE 13G |
| 27 Jul 2026 | SCHEDULE 13D/A |
| 23 Jul 2026 | SCHEDULE 13D/A |
| 20 Jul 2026 | 424B3 |
| 20 Jul 2026 | 424B3 |
| 20 Jul 2026 | 8-K: Submission of Matters to a Vote of Security Holders |
| 17 Jul 2026 | SCHEDULE 13D/A |
| 17 Jul 2026 | DEFA14A |
Loading...
